Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-853 in Japanese Patients With FR-alpha Positive Advanced Ovarian Cancer and Solid Tumors
NCT06390995Phase 2Active, not recruiting
- Sponsor
- Takeda
- Start
- May 2024
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mirvetuximab soravtansine in ovarian cancer, solid tumor, sponsored by Takeda. Started May 2024; status: active, not recruiting.
02
Drugs
mirvetuximab soravtansine
03
Conditions
ovarian cancersolid tumor
Beyond the preview
Go deeper on NCT06390995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06390995.